open access

Vol 2, No 2 (1999)
Published online: 2000-02-25
Submitted: 2012-01-23
Get Citation

Relationship of uptake of 99mTc-MIBI in bone metastases to efficiency of strontium-89 therapy in prostate cancer patients

Elena V. Barysheva, Sergey P. Selivanov, Julia E. Riannel, Svetlana N. Isaeva, Elena A. Usynin, Sergey A. Velichko, Wladimir Yu. Ussov
Nucl. Med. Rev 1999;2(2):63-68.

open access

Vol 2, No 2 (1999)
Published online: 2000-02-25
Submitted: 2012-01-23

Abstract

BACKGROUND: Although the pharmacokinetic profiles and clinical efficiency of 89SrCl2 as an agent of choice in extensive metastatic bone disease have been studied widely, the relationship of its efficiency to perfusion of metastases remains unresolved. Hence we aimed to compare the clinical and radiological manifestations of regression of metastatic bone disease in prostate cancer with results of pre-treatment scanning with 99mTc-MIBI as a blood flow marker.
MATERIALS AND METHODS: Sixteen patients with bone metastatic spread of prostate cancer (on average 9 s.d. 3 bone metastases on 99mTc-MDP scan) were treated with 89SrCl2 (Metastron, Amersham plc) and studied during post-injection followup. In each patient whole-body 99mTc-MDP (3–4h post-injection of 510 MBq) and 99mTc-MIBI (10 min post-injection of 510 MBq) scans were performed before injection of 150 MBq of 89SrCl2 and 3 and 6 months after. Mean count ratio (metastasis/normal bone) was calculated for 99mTc-MDP scans for all metastases. 99mTc-MIBI uptake was employed as a marker of local neoplastic blood flow in metastases, and quantified in a manner similar to 99mTc-MDP study as (metastasis/ normal bone) pixel count ratio. MRI T1 and T2 scanning were used for anatomic followup of metastases.
RESULTS: All patients demonstrated substantial improvement in severity of pain syndrome with full release from pain in ten. The 99mTc-MDP follow-up revealed a decrease in the number of «hot» metastatic uptake sites from 9 s.d. 3 to 5 s.d. 3 (p<0.01) with a simultaneous decrease of normal bone ratio in remaining hot spots on 99mTc-MDP scans from 2.79 s.d. 0.45 to 1.83 s.d. 0.18 (p<0.05) after 3 months and further to 1.44 s.d. 0.43 (p<0.05) after 6 months. Metastases with 99mTc-MIBI pre-treatment (metastasis/background) index over 1.5 and anatomic cross-dimensions below 19 mm demonstrated near-full regression when studied using 99mTc-MDP and MRI 3 and 6 months after injection of 89SrCl2. A significant correlation was observed between pre-treatment 99mTc-MIBI (Mts/Bg) ratio and decrease in 99mTc-MDP metastatic uptake (r=0.84, p<0.005).
CONCLUSION: Metastases with anatomic dimensions smaller than 20 mm and persistent blood supply can be effectively cured with 89Sr. The 99mTc-MIBI scan of bone metastases is of predictive value for prognosis of success of systemic 89Sr therapy in prostate cancer.

Abstract

BACKGROUND: Although the pharmacokinetic profiles and clinical efficiency of 89SrCl2 as an agent of choice in extensive metastatic bone disease have been studied widely, the relationship of its efficiency to perfusion of metastases remains unresolved. Hence we aimed to compare the clinical and radiological manifestations of regression of metastatic bone disease in prostate cancer with results of pre-treatment scanning with 99mTc-MIBI as a blood flow marker.
MATERIALS AND METHODS: Sixteen patients with bone metastatic spread of prostate cancer (on average 9 s.d. 3 bone metastases on 99mTc-MDP scan) were treated with 89SrCl2 (Metastron, Amersham plc) and studied during post-injection followup. In each patient whole-body 99mTc-MDP (3–4h post-injection of 510 MBq) and 99mTc-MIBI (10 min post-injection of 510 MBq) scans were performed before injection of 150 MBq of 89SrCl2 and 3 and 6 months after. Mean count ratio (metastasis/normal bone) was calculated for 99mTc-MDP scans for all metastases. 99mTc-MIBI uptake was employed as a marker of local neoplastic blood flow in metastases, and quantified in a manner similar to 99mTc-MDP study as (metastasis/ normal bone) pixel count ratio. MRI T1 and T2 scanning were used for anatomic followup of metastases.
RESULTS: All patients demonstrated substantial improvement in severity of pain syndrome with full release from pain in ten. The 99mTc-MDP follow-up revealed a decrease in the number of «hot» metastatic uptake sites from 9 s.d. 3 to 5 s.d. 3 (p<0.01) with a simultaneous decrease of normal bone ratio in remaining hot spots on 99mTc-MDP scans from 2.79 s.d. 0.45 to 1.83 s.d. 0.18 (p<0.05) after 3 months and further to 1.44 s.d. 0.43 (p<0.05) after 6 months. Metastases with 99mTc-MIBI pre-treatment (metastasis/background) index over 1.5 and anatomic cross-dimensions below 19 mm demonstrated near-full regression when studied using 99mTc-MDP and MRI 3 and 6 months after injection of 89SrCl2. A significant correlation was observed between pre-treatment 99mTc-MIBI (Mts/Bg) ratio and decrease in 99mTc-MDP metastatic uptake (r=0.84, p<0.005).
CONCLUSION: Metastases with anatomic dimensions smaller than 20 mm and persistent blood supply can be effectively cured with 89Sr. The 99mTc-MIBI scan of bone metastases is of predictive value for prognosis of success of systemic 89Sr therapy in prostate cancer.
Get Citation

Keywords

Strontium-89; bone metastases; 99mTc-MIBI; therapy; prognosis

About this article
Title

Relationship of uptake of 99mTc-MIBI in bone metastases to efficiency of strontium-89 therapy in prostate cancer patients

Journal

Nuclear Medicine Review

Issue

Vol 2, No 2 (1999)

Pages

63-68

Published online

2000-02-25

Bibliographic record

Nucl. Med. Rev 1999;2(2):63-68.

Keywords

Strontium-89
bone metastases
99mTc-MIBI
therapy
prognosis

Authors

Elena V. Barysheva
Sergey P. Selivanov
Julia E. Riannel
Svetlana N. Isaeva
Elena A. Usynin
Sergey A. Velichko
Wladimir Yu. Ussov

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl